EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics Versus Standard of Care Antibiotics and Diagnostics in Patients With Bloodstream Infection, Hospital-acquired Pneumonia or Ventilator-associated Pneumonia Due to Pseudomonas Aeruginosa or Carbapenemase Producing Enterobacterales (RAPID)
Blood Stream Infections, Ventilator Associated Pneumonia, Healthcare Associated Infection
About this trial
This is an interventional treatment trial for Blood Stream Infections focused on measuring rapid diagnostics, ceftazidime-avibactam, carbapenemase producing Enterobacterales, hospital-acquired, MDR, AMR, ASP, CRE, BCID2, PN Plus
Eligibility Criteria
Inclusion Criteria: patient developed clinical symptoms compatible with bloodstream infection, hospital-acquired or ventilator-associated pneumonia (hospital-acquired and ventilator-associated pneumonia should fulfil US CDC NHSN criteria) AND, an appropriate specimen has been received by the participating laboratory - that is, a blood culture bottle showing Gram negative bacilli or a respiratory sample collected for clinical purposes showing Gram negative bacilli on Gram stain; Exclusion Criteria: Refractory shock or comorbid condition such that patient not expected to survive more than 48 hours; OR, where the bloodstream infection is thought to be related to a vascular catheter and the catheter is unable to be removed; OR, treatment is not with the intent to cure the infection; OR, patient is incarcerated in a correctional facility; OR, patients previously randomised in this trial within the last 60 days.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Intervention
Control
Samples from patients randomised to the intervention arm will undergo the BioFire FilmArray systems. Patients will be then administered with the study drug, ceftazidime-avibactam when Pseudomonas aeruginosa or carbapenemase producing Enterobacterales detected.
Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics treatment will be administered as per usual institutional practice from hospital supplies.